Nuveen, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
295Shares Held
111MCall Options Held
2.57MPut Options Held
816K-
Wellington Management Group LLP Boston, MA12.3MShares$246 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$244 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$238 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$202 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$192 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.2B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...